Company intelligence / Profile preview

Paul Royalty Fund

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Paul Royalty Fund was a leading healthcare royalty fund established in the early 2000s, providing non-dilutive, product revenue-based financing to biopharma and medtech companies, often focusing on marketed or late-stage assets, and has invested over $1 billion across more than $625 million in transactions involving drugs such as Rotarix, Lunesta, and Zanaflex, but is no longer active as a current fund as of the 2010s[5][6][9].

Modalities: Small moleculeBiologicVaccineMedical device
Industry: Investors

Partnerships

Acorda Therapeutics (Zanaflex revenue participation)[1]Avant Immunotherapeutics (Rotarix royalty purchase)[1][5]Aventis (Lunesta royalty purchase)[1]Pharming (C1 inhibitor deal)[4]Glenmark Pharmaceuticals[8]Dyax[6]

Beyond the preview

Go deeper on Paul Royalty Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paul Royalty Fund.

Explore the full profile